Product Description
Our lead internal program in B-cell lymphoma unlocks a new frontier in CAR-T developments using our platform’s high frequencies of homology-directed repair to deliver in-vivo CAR insertions. (Sourced from: https://www.jenthera.com/programs)
Mechanisms of Action: CAR-T
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jenthera
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Lymphoma, B-Cell
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|